 |
 |
 |
 |
 |
 |
 |
|
Core Therapeutic Programs Schizophrenia is a chronic, severe, and disabling brain disease. Approximately 1 percent of the population develops schizophrenia during their lifetime - more than 2 million Americans suffer from the illness in a given year. It is characterized by the appearance of hallucinations and delusions, referred to as positive symptoms, and often a variety of other symptoms, including decreased social functioning and speech deficits, disorganized thought, and low motivation. The latter are often referred to as negative symptoms. Overlaying these symptom domains is a severe loss of cognitive function that may precede the appearance of the positive and negative symptoms. Further contributing to the disability of schizophrenia are common co-morbid illnesses, such as insomnia and depression, Available treatments primarily relieve the positive symptoms, but most people with schizophrenia continue to suffer many other symptoms throughout their lives. Current antipsychotics have various side effects, including the induction of extrapyramidal motor deficits, weight gain, Type II diabetes, cognitive impairment and daytime sedation. However, this is a time of hope for people with schizophrenia and their families. Research gradually is leading to new and safer medication and unraveling the complex causes of the disease. We believe ITI is at the forefront of the war against this debilitating disease, and ITI-007 could represent a major breakthrough in psychosis management. As a complimentary approach, ITI-002 is aimed at improving the disabling cognitive deficits associated with schizophrenia. Moreover, used as an adjunctive therapy to existing antipsychotic drugs, ITI-002 is designed to reduce antipsychotic-induced motor impairment and sedation by normalizing movement and enhancing daytime wakefulness.
|
